Search

Your search keyword '"Lobello, S"' showing total 149 results
Start Over Author "Lobello, S"
149 results on '"Lobello, S"'

4. Impact of HBV infection in HCV/HBV coinfected patients treated with DAAs IN Northern Italy

Author

Fabris, P., primary, Noventa, F., additional, Pasulo, L., additional, Farina, F., additional, Carollo, G., additional, Carlotto, A., additional, Rovere, P., additional, Cavinato, S., additional, Romano, A., additional, Vario, A., additional, Fraceschet, I., additional, Panese, S., additional, Bertin, T., additional, Zappalà, F., additional, Alberti, A., additional, Lobello, S., additional, Aghemo, A., additional, Bruno, R., additional, Puoti, M., additional, Rizzardini, G., additional, Spinelli, O., additional, Pigozzi, MG., additional, Spinetti, A., additional, Menzaghi, B., additional, Pan, A., additional, Bella, D., additional, Re, T., additional, Borghi, M., additional, Lombardi, A., additional, Viganò, M., additional, Salpietro, S., additional, Lleo, A., additional, and Fagiuoli, S., additional

Published
2020
Full Text
View/download PDF

8. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients

Author

Gambato, M., primary, Spinetti, A., additional, Pasulo, L., additional, D’ambrosio, R., additional, Puoti, M., additional, Schiavini, M., additional, Fabris, P., additional, Sacchi, P., additional, Gulminetti, R., additional, Carolo, G., additional, Scotton, P., additional, Franceschet, I., additional, Vinci, M., additional, Viganò, M., additional, Lobello, S., additional, Zuin, M.G., additional, Aghemo, A., additional, Rumi, M., additional, Carrara, M., additional, Manfrin, V., additional, Uberti-Foppa, C., additional, Panese, S., additional, Cattelan, F., additional, Paon, V., additional, Pan, A., additional, Spinelli, O., additional, Monforte, A. D’arminio, additional, Colli, A., additional, Spinzi, G., additional, Russo, F.P., additional, Chemello, L., additional, Vincenzi, V., additional, Grossi, P.A., additional, Buscarini, E., additional, Cardaci, G., additional, Soria, A., additional, Menzaghi, B., additional, Mendeni, M., additional, Degasperi, E., additional, Soffredini, R., additional, Colpani, M., additional, Comi, L., additional, Zuccaro, V., additional, Zaltron, S., additional, Gori, A., additional, Del Poggio, P., additional, Giorgini, A., additional, Capretti, A., additional, Memoli, M., additional, Pigozzi, M.G., additional, Rossi, M.C., additional, Cavalletto, L., additional, Capra, F., additional, Colombo, A., additional, Dibenedetto, C., additional, Landonio, S., additional, Noventa, F., additional, Lampertico, P., additional, Castelli, F., additional, Alberti, A., additional, and Fagiuoli, S., additional

Published
2019
Full Text
View/download PDF

15. Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network

Author

Invernizzi, F., primary, Pasulo, L., additional, Aghemo, A., additional, Puoti, M., additional, Zaltron, S., additional, Maggiolo, F., additional, Rizzardini, G., additional, Fargion, S., additional, Sacchi, P., additional, Gulminetti, R., additional, Zuin, M., additional, Quirino, T., additional, Rumi, M.G., additional, Pan, A., additional, Grossi, P., additional, Rossini, A., additional, Corbellini, A., additional, Uberti Foppa, C., additional, Belli, L., additional, Piovesan, S., additional, Angeli, P., additional, Chemello, L., additional, Russo, F.P., additional, Burra, P., additional, Vincenzi, V., additional, Cattelan, A.M., additional, Carolo, G., additional, Capra, F., additional, Carlotto, G., additional, Rovere, P.A., additional, Lobello, S., additional, Scotton, P., additional, Panese, S., additional, Fabris, P., additional, Alberti, A., additional, Lampertico, P., additional, and Fagiuoli, S., additional

Published
2018
Full Text
View/download PDF

16. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group

Author

Degasperi, E., primary, Pasulo, L., additional, Aghemo, A., additional, Puoti, M., additional, Zaltron, S., additional, Maggiolo, F., additional, Rizzardini, G., additional, Fargion, S., additional, Sacchi, P., additional, Gulminetti, R., additional, Zuin, M., additional, Quirino, T., additional, Rumi, M.G., additional, Pan, A., additional, Grossi, P., additional, Rossini, A., additional, Corbellini, A., additional, Uberti Foppa, C., additional, Colli, A., additional, Piovesan, S., additional, Angeli, P., additional, Chemello, L., additional, Russo, F.P., additional, Burra, P., additional, Vincenzi, V., additional, Cattelan, A.M., additional, Carolo, G., additional, Capra, F., additional, Carlotto, G., additional, Rovere, P.A., additional, Lobello, S., additional, Scotton, P., additional, Panese, S., additional, Fabris, P., additional, Alberti, A., additional, Lampertico, P., additional, and Fagiuoli, S., additional

Published
2018
Full Text
View/download PDF

18. Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?

Author

Milan, M, Boninsegna, S, Scribano, L, Lobello, S, Fagiuoli, S, Fabris, P, Buda, A, Martines, D, Milan M, Boninsegna S, Scribano L, Lobello S, Fagiuoli S, Fabris P, Buda A, Martines D, Milan, M, Boninsegna, S, Scribano, L, Lobello, S, Fagiuoli, S, Fabris, P, Buda, A, Martines, D, Milan M, Boninsegna S, Scribano L, Lobello S, Fagiuoli S, Fabris P, Buda A, and Martines D

Abstract

Background Pegylated interferon (PEG-IFN) and ribavirin is the most effective treatment for chronic hepatitis C virus (HCV) hepatitis, but the rate of sustained virological response (SVR) remains approximately 50%, and 15-20% of all treated patients have a virological relapse after completing the treatment. Studies on the SVR have failed to discriminate between non-responders and relapsers. Aims To identify the risk factors for relapse among patients with an end-of-treatment response (ETR). Methods We retrospectively analyzed 281 patients consecutively treated with PEG-IFN and ribavirin with a follow- up period of at least 24 weeks. The baseline details collected on each patient included demographic data, histological features, and biochemical profiles. Results Forty-six patients (16.4%) relapsed during the first 6 months of follow-up after discontinuing the therapy. Relapser patients were significantly older, had more steatosis, fibrosis, and showed significantly lower rapid virological response (RVR) rates compared with SVR patients. By logistic regression analysis, only the absence of RVR was found to be significantly associated with relapses in both subgroups of patients with genotypes 1 and 4 (p.004) and those with genotypes 2 and 3 (p.006). Severe fibrosis was also predictive of relapsing disease, but only for genotypes 2 and 3 patients (p.003). During the treatment, serum HCV-RNA decreased more rapidly in patients with SVR compared to non-responder and relapser patients (p.001). Interestingly, relapser patients exhibited an intermediate serum HCV-RNA decay during the first 4 weeks of therapy. Conclusion Among HCV patients treated with PEG-IFN and ribavirin, the absence of RVR was the most important independent predictor of relapse, independent of the HCV genotype. In the subgroup of genotypes 2 and 3 patients, the severity of fibrosis was also an important factor associated with the relapse rate.

Published
2012

19. Silybin conjugated with phosphatidilcholine and vitamin E improves liver damage in patients with NAFLD: the results of a randomized multicentre double-blind vs placebo trial

Author

Andreone P., Brisc M. C., Chiaramonte M., Floreani A., Freni M. A., Grieco A., Lobello S., Milani S., Okolicsanyi L., Portincasa P., Smedile A., Sporea I., Sorrentino F., Vecchione R., Tuccillo C., Loguercio C., FEDERICO, Alessandro, Andreone, P., Brisc, M. C., Chiaramonte, M., Federico, Alessandro, Floreani, A., Freni, M. A., Grieco, A., Lobello, S., Milani, S., Okolicsanyi, L., Portincasa, P., Smedile, A., Sporea, I., Sorrentino, F., Vecchione, R., Tuccillo, C., and Loguercio, C.

Published
2011

20. Preliminary results of A randomized multicentre double-blind vs placebo trial: evaluation of effect of silybin conjugated with phosphatidilcholine and vitamin E on liver damage in patients with nonalcoholic fatty liver disease

Author

Andreone P., Brisc M. C., Chiaramonte M., Floreani A., Freni M. A., Grieco A., Lobello S., Milani S., Okolicsanyi L., Portincasa P., Smedile A., Sporea I., Sorrentino F., Vecchione R., Tuccillo C., Loguercio C., FEDERICO, Alessandro, Andreone, P., Brisc, M. C., Chiaramonte, M., Federico, Alessandro, Floreani, A., Freni, M. A., Grieco, A., Lobello, S., Milani, S., Okolicsanyi, L., Portincasa, P., Smedile, A., Sporea, I., Sorrentino, F., Vecchione, R., Tuccillo, C., and Loguercio, C.

Published
2011

21. Effect of Silybin in patients with chronic hepatitis: preliminary results of a multicentre randomized controlled trial vs placebo

Author

FEDERICO, Alessandro, Andreone P., Brisc M. C., Chiaramonte M., Floreani A., Freni M. A., Grieco A., Lobello S., Milani S., Okolicsanyi L., Portincasa P., Smedile A., Sporea I., Vecchione R., Del Vecchio Blanco C., Loguercio C., Federico, Alessandro, Andreone, P., Brisc, M. C., Chiaramonte, M., Floreani, A., Freni, M. A., Grieco, A., Lobello, S., Milani, S., Okolicsanyi, L., Portincasa, P., Smedile, A., Sporea, I., Vecchione, R., Del Vecchio Blanco, C., and Loguercio, C.

Published
2010

22. Preliminary results of a multicentre randomized controlled trial with Silybin+phosphatidilcholine and vitamin E vs placebo in NASH patients

Author

FEDERICO, Alessandro, Andreone P., Brisc M. C., Chiaramonte M., Floreani A., Freni M. A., Grieco A., Lobello S., Milani S., Okolicsanyi L., Portincasa P., Smedile A., Sporea I., Sorrentino F., Vecchione R., Tuccillo C., Del Vecchio Blanco C., Loguercio C., Federico, Alessandro, Andreone, P., Brisc, M. C., Chiaramonte, M., Floreani, A., Freni, M. A., Grieco, A., Lobello, S., Milani, S., Okolicsanyi, L., Portincasa, P., Smedile, A., Sporea, I., Sorrentino, F., Vecchione, R., Tuccillo, C., Del Vecchio Blanco, C., and Loguercio, C.

Published
2010

23. Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal

Author

Floreani, A, Boninsegna, S, Lobello, S, Caroli, D, Fagiuoli, S, Floreani A, Boninsegna S, Lobello S, Caroli D, Fagiuoli S, Floreani, A, Boninsegna, S, Lobello, S, Caroli, D, Fagiuoli, S, Floreani A, Boninsegna S, Lobello S, Caroli D, and Fagiuoli S

Abstract

Lamivudine is a nucleoside analogue with a potent antiviral activity used as prophylaxis against hepatitis B virus reactivation in patients with chronic HBV infection receiving chemotherapy. No standard guidelines exist, however, for the duration of lamivudine treatment. We report a clinical case of a 56-year-old patient with HBeAg-negative cirrhosis who developed a multiple myeloma. He was treated with lamivudine for 1 year while receiving chemotherapy and a subsequent bone marrow transplant. Complete remission from multiple myeloma was achieved. Four months after lamivudine was withdrawn, he experienced HBV reactivation with jaundice, though no YMDD mutations were detected. The patient rapidly developed fatal decompensation with septicemia and renal failure. In conclusion, this case shows that physicians should avoid discontinuing nucleoside therapy in patients with HBV infection who undergo immunosuppresslon for concomitant neoplastic conditions.

Published
2006

29. LP52 : Nonalcoholic fatty liver disease (NAFLD) as potential risk factor of cardiovascular disease and oncological disease in diabetic type 2 patients

Author

Caroli, D., primary, Nogara, A., additional, Rosa-Rizzotto, E., additional, Bariga, A. Boscolo, additional, Zanoni, S., additional, De Boni, S., additional, Cavallarin, G., additional, Marafin, C., additional, Inglese, M., additional, Loggia, M. Della, additional, Peraro, L., additional, Lobello, S., additional, and De Lazzari, F., additional

Published
2015
Full Text
View/download PDF

31. P1282 A COST–CONSEQUENCE ANALYSIS OF SCREENING AND TREATMENT FOR CHRONIC HEPATITIS B (CHB) VIRUS INFECTION IN RESIDENT IMMIGRANTS OF AN ITALIAN NORTH-EAST REGION

Author

Rosa-Rizzotto, E., primary, Buja, A., additional, Martines, D., additional, Vinelli, A., additional, Bardelle, G., additional, Lopatriello, S., additional, Peraro, L., additional, Scribano, L., additional, Caroli, D., additional, De Lazzari, F., additional, Lobello, S., additional, and Baldo, V., additional

Published
2014
Full Text
View/download PDF

32. Hepatitis B virus screening in healthy immigrants: A strategy to prevent the spread of infection and to identify and manage chronic hepatitis B (CHB)

Author

Peraro, L., primary, Rosa-Rizzotto, E., additional, Piazza, A., additional, Caroli, D., additional, Gallo, S., additional, Magro, C., additional, Scribano, L., additional, Dal Bello, F., additional, D’Aquino, M.G., additional, De Lazzari, F., additional, Parisi, S., additional, Palù, G., additional, Martines, D., additional, and Lobello, S., additional

Published
2014
Full Text
View/download PDF

33. Hepatitis C virus in healthy immigrants: To screen or not to screen?

Author

Peraro, L., primary, Rosa-Rizzotto, E., additional, Piazza, A., additional, Caroli, D., additional, Gallo, S., additional, Magro, C., additional, Scribano, L., additional, Dal Bello, F., additional, D’Aquino, M.G., additional, Parisi, S., additional, Palù, G., additional, De Lazzari, F., additional, Martines, D., additional, and Lobello, S., additional

Published
2014
Full Text
View/download PDF

34. A cost-consequence analysis of screening and treatment for chronic hepatitis B (CHB) virus infection in resident immigrants of an Italian North-East

Author

Rosa-Rizzotto, E., primary, Buja, A., additional, Martines, D., additional, Vinelli, A., additional, Bardelle, G., additional, Lopatriello, S., additional, Peraro, L., additional, Scribano, L., additional, Caroli, D., additional, De Lazzari, F., additional, Lobello, S., additional, and Baldo, V., additional

Published
2014
Full Text
View/download PDF

36. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial

Author

Loguercio, C, Andreone, P, Brisc, C, Brisc, Mc, Bugianesi, E, Chiaramonte, M, Cursaro, C, Danila, M, De Sio, I, Floreani, A, Freni, Ma, Grieco, Antonio, Groppo, Mario, Lazzari, R, Lobello, S, Lorefice, E, Margotti, M, Miele, Luca, Milani, Silvia, Okolicsanyi, L, Palasciano, G, Portincasa, P, Saltarelli, P, Smedile, A, Somalvico, F, Spadaro, A, Sporea, I, Sorrentino, P, Vecchione, R, Tuccillo, C, Del Vecchio Blanco, C, Federico, A., Grieco, Antonio (ORCID:0000-0002-0544-8993), Miele, Luca (ORCID:0000-0003-3464-0068), Loguercio, C, Andreone, P, Brisc, C, Brisc, Mc, Bugianesi, E, Chiaramonte, M, Cursaro, C, Danila, M, De Sio, I, Floreani, A, Freni, Ma, Grieco, Antonio, Groppo, Mario, Lazzari, R, Lobello, S, Lorefice, E, Margotti, M, Miele, Luca, Milani, Silvia, Okolicsanyi, L, Palasciano, G, Portincasa, P, Saltarelli, P, Smedile, A, Somalvico, F, Spadaro, A, Sporea, I, Sorrentino, P, Vecchione, R, Tuccillo, C, Del Vecchio Blanco, C, Federico, A., Grieco, Antonio (ORCID:0000-0002-0544-8993), and Miele, Luca (ORCID:0000-0003-3464-0068)

Abstract

The only currently recommended treatment for nonalcoholic fatty liver disease (NAFLD) is lifestyle modification. Preliminary studies of silybin showed beneficial effects on liver function. Realsil (RA) comprises the silybin phytosome complex (silybin plus phosphatidylcholine) coformulated with vitamin E. We report on a multicenter, phase III, double-blind clinical trial to assess RA in patients with histologically documented NAFLD. Patients were randomized 1:1 to RA or placebo (P) orally twice daily for 12 months. Prespecified primary outcomes were improvement over time in clinical condition, normalization of liver enzyme plasma levels, and improvement of ultrasonographic liver steatosis, homeostatic model assessment (HOMA), and quality of life. Secondary outcomes were improvement in liver histologic score and/or decrease in NAFLD score without worsening of fibrosis and plasma changes in cytokines, ferritin, and liver fibrosis markers. We treated 179 patients with NAFLD; 36 were also HCV positive. Forty-one patients were prematurely withdrawn and 138 patients analyzed per protocol (69 per group). Baseline patient characteristics were generally well balanced between groups, except for steatosis, portal infiltration, and fibrosis. Adverse events (AEs) were generally transient and included diarrhea, dysgeusia, and pruritus; no serious AEs were recorded. Patients receiving RA but not P showed significant improvements in liver enzyme plasma levels, HOMA, and liver histology. Body mass index normalized in 15% of RA patients (2.1% with P). HCV-positive patients in the RA but not the P group showed improvements in fibrogenesis markers. This is the first study to systematically assess silybin in NAFLD patients. Treatment with RA but not P for 12 months was associated with improvement in liver enzymes, insulin resistance, and liver histology, without increases in body weight. These findings warrant further investigation.

Published
2012

38. Colchicine in chronic hepatitis B: a pilot study

Author

Chiaramonte, M, Aneloni, V, Brunetto, M, Lobello, S, and Floreani, A.

Subjects
Adult, Male, Hepatitis B virus, Administration, Oral, Pilot Projects, Middle Aged, Gout Suppressants, Hepatitis B, Chronic, Liver Function Tests, DNA, Viral, Humans, Female, Colchicine, Aged
Abstract

Because of its antifibrotic and anti-inflammatory effects, colchicine has been proposed as a treatment for liver disease. Early in vitro studies have demonstrated that colchicine blocks mitosis in the metaphase and inhibits DNA synthesis.A pilot study of hepatitis B virus (HBV)-related/HBV-DNA+ve chronic liver disease.Nine biopsy-proven chronic hepatitis patients (three with cirrhosis) entered the study. Two of them were HBeAg+ve and seven were antiHBe+. All patients were HBV-DNA+ve/antiHBc IgM+ve (index values of anti-HBc IgM ranged from 0.370 to 1.200). All of them had a major contraindication to interferon therapy or refused antiviral treatment. The known persistence of positive HBsAg ranged from 2 to 21 years.After informed consent, the patients received 1 mg colchicine a day orally for 5 days-a-week over 6 months. Testing for liver enzymes and viral markers was performed at the baseline and after 3 and 6 months.None of the patients experienced side-effects during the treatment. The two HBeAg+ve patients seroconverted to anti-HBe with a normalization of AST/ALT during therapy. Among the seven antiHBe+ve patients, four had a complete normalization of transaminases (one patient cleared the HBsAg with seroconversion to anti-HBs). Six of the nine patients were HBV-DNA-ve at the end of therapy and were still negative after 12 months of follow-up.These preliminary results suggest that colchicine might have an antiviral activity in HBV-DNA+ve chronic liver disease, and it could be regarded as an alternative therapy to interferon.

Published
1998

39. Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring

Author

Chiaramonte, M, Brunetto, Mr, Floreani, A, Vian, A, Lorenzoni, U, and Lobello, S.

Subjects
Adult, Liver Cirrhosis, Male, Hepatitis B virus, Adolescent, Biopsy, Interferon-alpha, Alanine Transaminase, Pilot Projects, Middle Aged, Antiviral Agents, Hepatitis B Core Antigens, Hepatitis B Antigens, Hepatitis B, Chronic, Immunoglobulin M, Liver, DNA, Viral, Humans, Female, Hepatitis B e Antigens, Drug Monitoring, Hepatitis B Antibodies, Follow-Up Studies, Retrospective Studies
Abstract

Chronic hepatitis B infection with the hepatitis B e antigen (HBeAg)-negative variant is associated with a severe clinical course and a low response rate to interferon (IFN). In an attempt to improve the chances of sustained response to interferon we designed a pilot study, using titres of IgM antibodies to hepatitis B core antigen (HBcAb IgM) to guide treatment initiation. Eighteen adults who were HBeAg-negative with biopsy-proven chronic active hepatitis (seven with cirrhosis) entered the study. They were followed-up bimonthly with routine liver function tests, and HBcAb IgM titres were also determined. Treatment (lymphoblastoid IFN 5 million units (MU) m(-2) three times weekly for 6 months) was started when the HBcAb IgM titre was increasing. Fifteen (83.3%) patients had normal alanine aminotransferase (ALT) levels and undetectable HBV DNA at the end of treatment. HBcAb IgM decreased in all responders. We observed a relapse in four patients (three with cirrhosis), in the first year after treatment, with an increase in ALT, HBV DNA and titre of HBcAb IgM. Eleven patients (61.1%) had a sustained response and eight of these 11 patients were followed-up for more than 18 months; two responders cleared hepatitis B surface antigen (HBsAg). Hence, the rate of sustained response to IFN in HBeAb-positive patients with chronic hepatitis is improved if treatment is started when HBcAb IgM levels are increasing.

Published
1998

40. O6 * FREE ORAL COMMUNICATIONS 6: PSYCHOSOCIAL FACTORS AND ALCOHOL USE DISORDERS

Author

Zullino, D., primary, Achab, S., additional, Thorens, G., additional, Khan, R., additional, Manghi, R., additional, Khazaal, Y., additional, Lallemand, F., additional, Ward, R., additional, De Witte, P., additional, Caroli, D., additional, Rosa-Rizzotto, E., additional, Peraro, L., additional, Cocchio, S., additional, Baldo, V., additional, Simoncello, I., additional, Vendramin, A., additional, De Lazzari, F., additional, Lobello, S., additional, Van den Berg, J., additional, Hermes, J., additional, Van den Brink, W., additional, Blanken, P., additional, Kist, N., additional, and Kok, R., additional

Published
2013
Full Text
View/download PDF

41. O4 * FREE ORAL COMMUNICATIONS 4: ALCOHOL INTERVENTIONS IN DIFFERENT SETTINGS

Author

Moirand, R., primary, Gomez, C. D., additional, Ngantcha, M., additional, Legarjean, N., additional, Travers, D., additional, Le Lan, C., additional, Guillery, X., additional, Perennes, M., additional, Kerdiles, F. J., additional, Brouard, N., additional, Lasbleiz, M., additional, Bellou, A., additional, Lobello, S., additional, Rosa-Rizzotto, E., additional, Peraro, L., additional, Caroli, D., additional, Polato, F., additional, Vendramin, A., additional, De Lazzari, F., additional, Barroso, T., additional, Jorge, M., additional, Vonkova, H., additional, Miovsky, M., additional, Gabrhelik, R., additional, and Cablova, L., additional

Published
2013
Full Text
View/download PDF

42. EPIDEMIOLOGY

Author

Caamano-Isorna, F., primary, Ramkumar, M.-R., additional, Doallo, S., additional, Corral, M., additional, Rodriguez-Holguin, S., additional, Cadaveira, F., additional, Nemtsov, A. V., additional, Gilder, D., additional, Ehlers, C., additional, Gizer, I., additional, Yehuda, R., additional, Razvodovsky, Y., additional, Thorens, G., additional, Achab, S., additional, Peraro, L., additional, Lobello, S., additional, Rosa-Rizzotto, E., additional, Caroli, D., additional, Polato, F., additional, De Lazzari, F., additional, Grinakis, E., additional, Stathaki, D., additional, Sfakianaki, E., additional, Mouzas, J., additional, Salem, B., additional, Lesch, O. M., additional, Mouzas, I., additional, Koulentaki, M., additional, Liodaki, N., additional, Sfakianaki, K., additional, Pikraki, K., additional, Aggouridaki, R., additional, Hovhannisyan, K., additional, Skagert, E., additional, Thornqvist, K., additional, Ohlsson, M., additional, Wikstrom, M. M., additional, Tonnesen, H., additional, Anderson, P., additional, Gual, A., additional, Spak, F., additional, Bendtsen, P., additional, Keurhorst, M., additional, Segura, L., additional, Colom, J., additional, Reynolds, J., additional, Drummond, C., additional, Deluca, P., additional, van Steenkiste, B., additional, Mierzecki, A., additional, Kloda, K., additional, Wallace, P., additional, Newbury-Birch, D., additional, Kaner, E., additional, Laurant, M., additional, and Wojnar, M., additional

Published
2013
Full Text
View/download PDF

45. 1280 NAFLD/NASH: MUCH ADO ABOUT NOTHING? A 25 YRS RETROSPECTIVE STUDY IN A COHORT OF DIABETIC PATIENTS

Author

CAROLI, D., primary, Del Bianco, P., additional, Nogara, A., additional, Rosa-Rizzotto, E., additional, Peraro, L., additional, Lobello, S., additional, De Lazzari, F., additional, Maraffin, C., additional, Cavallarin, G., additional, De Boni, S., additional, Loggia, M. Della, additional, Zanoni, S., additional, and Bariga, A. Boscolo, additional

Published
2012
Full Text
View/download PDF

46. P.03.18 NAFLD/NASH: MUCH ADO ABOUT NOTHING? A 25 YRS RETROSPECTIVE STUDY IN A COHORT OF DIABETIC PATIENTS

Author

Caroli, D., primary, Del Bianco, P., additional, Nogara, A., additional, Rizzotto, E. Rosa, additional, Peraro, L., additional, Lobello, S., additional, De Lazzari, F., additional, Marafin, C., additional, Cavallarin, G., additional, De Boni, S., additional, Loggia, M. Della, additional, Zanoni, S., additional, and Bariga, A. Boscolo, additional

Published
2012
Full Text
View/download PDF

49. 825 SILYBIN CONJUGATED WITH PHOSPHATIDYLCHOLINE AND VITAMIN E IMPROVES LIVER DAMAGE IN PATIENTS WITH NAFLD: THE RESULTS OF A RANDOMIZED MULTICENTRE DOUBLE-BLIND VS PLACEBO TRIAL

Author

Andreone, P., primary, Brise, M.C., additional, Chiaramonte, M., additional, Federico, A., additional, Floreani, A., additional, Freni, M.A., additional, Grieco, A., additional, Lobello, S., additional, Milani, S., additional, Okolicsanyi, L., additional, Portincasa, P., additional, Smedile, A., additional, Sporea, I., additional, Sorrentino, P., additional, Vecchione, R., additional, Tuccillo, C., additional, and Loguercio, C., additional

Published
2011
Full Text
View/download PDF

50. F-49 A randomized multicentre double-blind vs placebo trial: Evaluation of effect of silybin conjugated with phosphatidilcholine and vitamin E on liver damage in patients with nonalcoholic fatty liver disease

Author

Andreone, P., primary, Brisc, M.C., additional, Chiaramonte, M., additional, Federico, A., additional, Floreani, A., additional, Freni, M.A., additional, Grieco, A., additional, Lobello, S., additional, Milani, S., additional, Okolicsanyi, L., additional, Portincasa, P., additional, Smedile, A., additional, Sporea, I., additional, Sorrentino, P., additional, Vecchione, R., additional, Tuccillo, C., additional, and Loguercio, C., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results